Evelo Biosciences & Abdul Latif Jameel Health Announce Strategic Collaboration
YAHOO! Finance reports on a strategic collaboration expected to accelerate access to Evelo’s lead inflammation product candidate and COVID-19 therapeutic medicine EDP1815 to people in select developing markets as Abdul Latif Jameel Health’s first biotechnology licensing agreement.
“We are honored to be selected as Abdul Latif Jameel Health’s first therapeutic biotech collaborator,”Simba Gill, Ph.D., Chief Executive Officer of Evelo.
Read the full article in its original location here.